The results of our quantitative synthesis suggest that there is no significant association between ABCB1 G2677T/A polymorphism and breast cancer risk in overall comparisons under four genetic models (heterozygote: OR = 1.01, 95% CI = 0.92-1.09, P = 0.90; homozygote: OR = 1.01, 95% CI = 0.65-1.55, P = 0.97; recessive model: OR = 1.06, 95% CI = 0.75-1.50, P = 0.76; and dominant model: OR = 0.98, 95% CI = 0.77-1.24, P = 0.85).
These results suggest that ABCB1 gene C3435T, G2677T/A variations and haplotype 3435T-1236T-2677T relate to the risk and clinical outcomes of breast carcinoma and may function as candidate molecular markers of anthracycline chemosensitivity in breast carcinoma.
Whether ABCB1 polymorphisms including T-129C, A61G, C1236T, G2677T/A and C3435T polymorphisms could account for variations in the disposition of docetaxel and whether menopausal status at the time of diagnosis might interact with this effect were analysed in women receiving neoadjuvant chemotherapy for breast cancer (n=86).